Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
3 December 2018 16:00 GMT
Transparency Directive
Voting Rights and Capital
The
following notification is made in accordance with the UK Financial
Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at
30 November 2018 the issued share capital of AstraZeneca PLC with
voting rights is 1,266,811,703 ordinary shares of US$0.25. No
shares are held in Treasury. Therefore, the total number of voting
rights in AstraZeneca PLC is 1,266,811,703.
The above figure for the total number of voting rights may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, AstraZeneca PLC under the UK
Financial Conduct Authority's Disclosure and Transparency
Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
For more information, please visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203 749 5916
|
|
Jennifer
Hursit
|
UK/Global
|
+44 7384 799 726
|
|
Jacob
Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
Cardiovascular; Metabolism
|
+44 203 749 5711
|
|
Nick
Stone
|
Respiratory; Renal
|
+44 203 749 5716
|
|
Josie
Afolabi
|
Other
|
+44 203 749 5631
|
|
Craig
Marks
|
Finance; Fixed Income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Retail Investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 7277
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
03 December
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|